Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
9601007 | Clinical Oncology | 2005 | 6 Pages |
Abstract
In this study, serial neurologic assessment of patient symptoms and signs seemed to be a better indicator of a possible glutamine effect than sensory- or motor-nerve-conduction studies. Prospective randomised trials are needed to clarify the effect of glutamine on paclitaxel and other types of chemotherapy-induced neuropathy.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
M.D. Stubblefield, L.T. Vahdat, C.M. Balmaceda, A.B. Troxel, C.S. Hesdorffer, C.L. Gooch,